Septerna, Inc. (SEPN) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Septerna, Inc. is a biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company operates in endocrinology, immunology, and metabolic diseases. As of the filing date, Septerna is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0.2 million | $0.3 million |
| Net Loss | $(21.5) million | $(14.2) million |
| Net Loss Per Share (Basic & Diluted) | $(0.49) | $(6.35) |
| Operating Expenses | $26.1 million | $15.8 million |
| Cash, Cash Equivalents & Marketable Securities | $398.2 million | $239.1 million (Beginning Q1 2025) |
| Net Cash Used in Operating Activities | $(23.3) million | $(16.7) million |
| Accumulated Deficit | $(139.9) million | $(60.7) million (Q1 2024) |
Note: Revenue is derived solely from research services (Vertex agreement). The company has no product sales revenue.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $10.3 million (65%) year-over-year.
- R&D Expenses: Increased by $6.1 million to $19.3 million, driven by higher direct costs for clinical/preclinical programs (including $1.7M in clinical trial expenses) and increased payroll.
- G&A Expenses: Increased by $4.2 million to $6.9 million, primarily due to legal/consulting fees associated with public company compliance post-IPO and increased headcount.
- Higher Interest Income: Interest income increased by $3.2 million to $4.5 million due to higher interest rates and larger cash balances following the October 2024 IPO.
- Discontinuation of Program: The SEP-786 clinical study was discontinued in February 2025; significant additional costs for this study are not anticipated.
- Stock-Based Compensation: Increased to $1.5 million from $0.6 million year-over-year.
Guidance, Outlook, and Material Events
- Novo Nordisk Collaboration (Subsequent Event): On May 13, 2025, Septerna entered into a global Collaboration and License Agreement with Novo Nordisk A/S.
- Upfront Payment: $195.0 million non-refundable upfront payment upon effectiveness.
- Milestones: Eligible for up to $498.0 million per R&D program (four programs initially) in research, development, regulatory, and commercial milestones.
- Royalties: Escalating tiered royalties (mid-to-high single-digits) on global net sales.
- Impact: Management expects the upfront payment to significantly extend the cash runway beyond the previously guided early 2028 horizon.
- Liquidity: As of March 31, 2025, the company held $398.2 million in cash and marketable securities, sufficient to fund operations for at least 12 months. The Novo deal is expected to further bolster liquidity.
- Risks: Key risks include the uncertainty of clinical trial outcomes, potential FDA staffing disruptions due to government budget changes, and geopolitical/tariff impacts on supply chains.
Investor Verification Checklist
- Novo Nordisk Deal Closing: Verify the effectiveness date of the Collaboration Agreement and the receipt of the $195 million upfront payment.
- Cash Runway Update: Confirm the updated cash runway guidance post-Novo transaction closing.
- Program Pipeline Status: Monitor progress on the PTH1R and SEP-631 (MRGPRX2) programs following the discontinuation of SEP-786.
- Regulatory Environment: Assess potential impacts of FDA staffing reductions and government funding changes on IND submissions and review timelines.
- Expense Trajectory: Track whether R&D and G&A expenses stabilize or continue to increase as the company scales operations.